Author

Xavier Segarra-Visent

Universitätsklinikum Tübingen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 2 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

Anastasia Kremer· 3 shared Dimas EcheverriaiD· 3 shared Melanie SaueriD· 3 shared Réka Ágnes HarasztiiD· 3 shared Tatyana Ryaykenen· 3 shared David A. Cooper· 2 shared Leon Breuer· 2 shared Clothilde PhilouzeiD· 1 shared

Activity by Year

2025-2025 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBioengineering

Anastasia Kremer

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cryopreservation of siRNA-treated cells is feasible

Melanie Sauer, Xavier Segarra-Visent, Leon Breuer, Vasileios Tzirtziganis, Tatyana Ryaykenen, David A. Cooper, Dimas Echeverria, Anastasia Kremer, Réka Ágnes Haraszti

This study shows that cryopreservation of siRNA-treated cells maintains silencing efficacy, with optimal siRNA exposure duration and temperature.

Nucleic Acid Therapeutics · Sep 24, 2025Peer-reviewedBioengineering

Structure - silencing duration relationships in RNAi medicines in rapidly dividing cells

Anastasia Kremer, Tatyana Ryaykenen, Xavier Segarra-Visent, Melanie Sauer, Leon Breuer, Yi‐Ying Wu, Qi Tang, David A. Cooper, Dimas Echeverria, Clothilde Philouze, Emilie Bayon, Dan Georgess, Réka Ágnes Haraszti

This study examines how chemical modifications affect the duration of RNAi-based therapies in rapidly dividing cells, finding that specific modifications can extend silencing duration significantly.

Molecular Therapy · Aug 12, 2025Peer-reviewedPharmacology & Toxicology

miRNA Mimic Optimization: Chemical Structure - Activity - Targetome Relationship to Engineer Selective Anti-Tumor Immunity in T cells

Xavier Segarra-Visent, Tatyana Ryaykenen, Anastasia Kremer, Melanie Sauer, Samuel Jackson, David Cooper, Dimas Echeverria, Réka Ágnes Haraszti

This study identifies a miR-374b mimic that selectively inhibits GVHD while enhancing GvL, demonstrating the potential of chemically modified miRNA therapies to improve T-cell-based cancer treatments.

bioRxiv · Apr 16, 2025 · PreprintBioengineering